Skip to main content
Signal8

Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC

$CRDLPress releaseNov 3, 2026, 5:04 PM ETRead the release

Cardiol Therapeutics entered into an at-the-market equity offering agreement with Jefferies LLC allowing it to sell up to US$75 million of common shares from time to time at prevailing market prices on Nasdaq. Sales under the program are discretionary, with proceeds earmarked for CardiolRx development in recurrent pericarditis — including a New Drug Application pending Phase III MAVERIC trial outcomes — plus CRD-38 clinical development and general corporate expenses.

Key figures

Deal Value Usd
75000000
Sales agent
Jefferies LLC
Program type
at-the-market (ATM) equity program
Max shares value usd
75000000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.